These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 24056649)

  • 1. Importance of P53, Ki-67 expression in the differential diagnosis of benign/malignant phyllodes tumors of the breast.
    Kucuk U; Bayol U; Pala EE; Cumurcu S
    Indian J Pathol Microbiol; 2013; 56(2):129-34. PubMed ID: 24056649
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathologic, immunohistochemical, and molecular features of benign and malignant phyllodes tumors of the breast.
    Kleer CG; Giordano TJ; Braun T; Oberman HA
    Mod Pathol; 2001 Mar; 14(3):185-90. PubMed ID: 11266524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An approach to malignant mammary phyllodes tumors detection.
    Ilić I; Randelović P; Ilić R; Katić V; Milentijević M; Velicković L; Krstić M
    Vojnosanit Pregl; 2009 Apr; 66(4):277-82. PubMed ID: 19441158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between NF-κB, ER, PR, Her2/neu, Ki67, p53 expression in human breast cancer.
    Shapochka DO; Zaletok SP; Gnidyuk MI
    Exp Oncol; 2012 Dec; 34(4):358-63. PubMed ID: 23302996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma.
    Khalifeh IM; Albarracin C; Diaz LK; Symmans FW; Edgerton ME; Hwang RF; Sneige N
    Am J Surg Pathol; 2008 Apr; 32(4):544-52. PubMed ID: 18300793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p53 protein expression and gene mutation in phyllodes tumors of the breast.
    Gatalica Z; Finkelstein S; Lucio E; Tawfik O; Palazzo J; Hightower B; Eyzaguirre E
    Pathol Res Pract; 2001; 197(3):183-7. PubMed ID: 11314782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased p53 protein expression in malignant mammary phyllodes tumors.
    Tse GM; Putti TC; Kung FY; Scolyer RA; Law BK; Lau TS; Lee CS
    Mod Pathol; 2002 Jul; 15(7):734-40. PubMed ID: 12118111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utility of Ki-67, CD10, CD34, p53, CD117, and mast cell content in the differential diagnosis of cellular fibroadenomas and in the classification of phyllodes tumors of the breast.
    Vilela MH; de Almeida FM; de Paula GM; Ribeiro NB; Cirqueira MB; Silva AL; Moreira MA
    Int J Surg Pathol; 2014 Sep; 22(6):485-91. PubMed ID: 24492332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing the impact of polysomy-17 on HER2 status and the correlations of HER2 status with prognostic variables (ER, PR, p53, Ki-67) in epithelial ovarian cancer: a tissue microarray study using immunohistochemistry and fluorescent in situ hybridization.
    Lin CK; Lin WL; Chen FL; Lee MY; Kuo JF; Ruan A; Tyan YS; Chiang H; Chou MC; Han CP
    Int J Gynecol Pathol; 2011 Jul; 30(4):372-9. PubMed ID: 21623202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apocrine ductal carcinoma in situ of the breast: histologic classification and expression of biologic markers.
    Leal C; Henrique R; Monteiro P; Lopes C; Bento MJ; De Sousa CP; Lopes P; Olson S; Silva MD; Page DL
    Hum Pathol; 2001 May; 32(5):487-93. PubMed ID: 11381366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of p53 protein and Ki-67 antigen in phyllodes tumor of the breast.
    Chan YJ; Chen BF; Chang CL; Yang TL; Fan CC
    J Chin Med Assoc; 2004 Jan; 67(1):3-8. PubMed ID: 15077883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p53 and c-erbB-2 protein expression in breast carcinomas. An immunohistochemical study including correlations with receptor status, proliferation markers, and clinical stage in human breast cancer.
    Barbareschi M; Leonardi E; Mauri FA; Serio G; Dalla Palma P
    Am J Clin Pathol; 1992 Oct; 98(4):408-18. PubMed ID: 1357956
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunoreactivity of p53, Ki-67, and c-erbB-2 in phyllodes tumors of the breast in correlation with clinical and morphologic features.
    Shpitz B; Bomstein Y; Sternberg A; Klein E; Tiomkin V; Kaufman A; Groisman G; Bernheim J
    J Surg Oncol; 2002 Feb; 79(2):86-92. PubMed ID: 11815995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phyllodes tumors and fibroadenoma common beginning and different ending.
    Oprić S; Oprić D; Gugić D; Granić M
    Coll Antropol; 2012 Mar; 36(1):235-41. PubMed ID: 22816226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estrogen receptor-negative and human epidermal growth factor receptor 2-negative breast cancer tissue have the highest Ki-67 labeling index and EGFR expression: gene amplification does not contribute to EGFR expression.
    Umemura S; Takekoshi S; Suzuki Y; Saitoh Y; Tokuda Y; Osamura RY
    Oncol Rep; 2005 Aug; 14(2):337-43. PubMed ID: 16012712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD34, CD117, and actin expression in phyllodes tumor of the breast.
    Chen CM; Chen CJ; Chang CL; Shyu JS; Hsieh HF; Harn HJ
    J Surg Res; 2000 Dec; 94(2):84-91. PubMed ID: 11104647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phyllodes tumor of the breast: EGFR family expression and relation to clinicopathological features.
    Suo Z; Nesland JM
    Ultrastruct Pathol; 2000; 24(6):371-81. PubMed ID: 11206334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hormone receptors expression in phyllodes tumors of the breast.
    Kim YH; Kim GE; Lee JS; Lee JH; Nam JH; Choi C; Park MH; Yoon JH
    Anal Quant Cytol Histol; 2012 Feb; 34(1):41-8. PubMed ID: 22590818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Topoisomerase II alpha expression and the Ki-67 labeling index correlate with prognostic factors in estrogen receptor-positive and human epidermal growth factor type-2-negative breast cancer.
    Tokiniwa H; Horiguchi J; Takata D; Kikuchi M; Rokutanda N; Nagaoka R; Sato A; Odawara H; Tozuka K; Oyama T; Takeyoshi I
    Breast Cancer; 2012 Oct; 19(4):309-14. PubMed ID: 21725655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.